



Docket No.: LEN 102

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

Corres. and Mail
BOX AF

RE: Application Serial No.: 09/709,045

Applicants: M. Rigdon LENTZ

Filing Date: November 10, 2000

For: METHOD AND SYSTEM TO REMOVE CYTOKIN
INHIBITOR IN PATIENTS

Group Art Unit: 1647

Examiner: L. SPECTOR

SIR:


Attached hereto for filing are the following papers:

**Amendment under C.F.R. §1.116 Expedited Prosecution; 37
C.F.R. 41.202 Suggestion of an Interference; & Copy of U.S. 6,379,708**

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.




James J. Kelly, Ph.D.
Registration No. 41,504

Customer Number

22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)



ATTORNEYS AT LAW

JAMES J. KELLY, PH.D.
(703) 413-3000
JKELLY@OBLO.COM

DOCKET NO: LEN 102



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :
M. RIGDON LENTZ : EXAMINER: L. SPECTOR
SERIAL NO: 09/709,045 :
FILED: NOVEMBER 10, 2000 : GROUP ART UNIT: 1647
FOR: METHOD AND SYSTEM TO :
REMOVE CYTOKINE INHIBITOR IN :
PATIENTS

AMENDMENT UNDER C.F.R. 1.116
EXPEDITED PROSECUTION

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Office Action dated January 6, 2005, Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

A discussion of the **Support for the Amendments** begins on page 5 of this paper.

Remarks begin on page 8 of this paper.